In vitro comparison of bradykinin degradation by aliskiren, a renin inhibitor, and an inhibitor of angiotensin-converting enzyme

Conclusion:
Aliskiren has no effect upon the rate of bradykinin degradation in plasma and a minimal effect employing vascular endothelial cells. The latter suggests inhibition of a non-renin enzyme that is a minor contributor to bradykinin degradation.

Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS - June 12, 2015 Category: Biomedical Science Authors: Joseph, K., Tholanikunnel, T. E., Kaplan, A. P. Tags: Original Articles Source Type: research